Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Cureus ; 11(6): e4847, 2019 Jun 06.
Article in English | MEDLINE | ID: mdl-31410330

ABSTRACT

INTRODUCTION: Wide-necked intracranial aneurysms (IAs) are complex lesions that may require different microsurgical or endovascular strategies, and stent-assisted coiling (SAC) has emerged as a feasible alternative to treat this subset of aneurysms. METHODS: The objective was to assess the rate of complications of unruptured wide-necked IAs treated with SAC. We retrospectively identified patients with unruptured wide-necked IAs treated with SAC. Medical charts, procedure reports, and imaging studies were analyzed. RESULTS: One hundred twenty patients harboring 124 unruptured wide-necked IAs were included. Ninety-two aneurysms (74.2%) were located in the anterior circulation. The median aneurysm size was 7 mm (IQR = 5-10). The immediate complete aneurysm occlusion rate was 29% (36/124). The rate of procedural complications was 3.3 % (4/120), which included 2 intraprocedural aneurysm ruptures, 1 immediate postprocedure aneurysm rupture, and 1 vessel occlusion rescued with an open-cell stent. The median follow-up time was 21 months (IQR = 10.3-40.9). Kaplan-Meier analysis estimated a median time of complete aneurysm occlusion of 6.3 months (95%CI = 3.8-7.8). At 30-day follow-up, 80.7% of patients had a Glasgow Outcome Score (GOS) of 5 and at the latest follow-up 83.9%. Imaging follow-up was available for 102 patients. The rate of complete aneurysm occlusion was 73.5% (75/102), severe in-stent stenosis (>50%) was found in 1% (1/102), the recanalization rate was 6.6% (5/75), and the retreatment rate was 7.8% (8/102). CONCLUSION: SAC remains a safe and effective technique to treat wide-necked IAs, providing a low rate of complications and recanalization with excellent long-term aneurysm occlusion rates.

2.
Neurosurgery ; 84(6): E402-E409, 2019 06 01.
Article in English | MEDLINE | ID: mdl-30239959

ABSTRACT

BACKGROUND: The Pipeline Flex (PED Flex; Medtronic, Dublin, Ireland) was designed to facilitate deployment and navigation compared to its previous iteration to reduce the rate of technical events and complications. OBJECTIVE: To assess the neurological morbidity and mortality rates of the PED Flex at 30 d. METHODS: Information from 9 neurovascular centers was retrospectively obtained between July 2014 and March 2016. Data included patient/aneurysm characteristics, periprocedural events, clinical, and angiographic outcomes. Multivariate logistic regression was performed to determine predictors of unfavorable clinical outcome (modified Rankin Scale [mRS] > 2). RESULTS: A total of 205 patients harboring 223 aneurysms were analyzed. The 30-d neurological morbidity and mortality rates were 1.9% (4/205) and 0.5% (1/205), respectively. The rate of intraprocedural events without neurological morbidity was 6.8% (14/205), consisting of intraprocedural ischemic events in 9 patients (4.5%) and hemorrhage in 5 (2.4%). Other technical events included difficulty capturing the delivery wire in 1 case (0.5%) and device migration after deployment in another case (0.5%). Favorable clinical outcome (mRS 0-2) was achieved in 186 patients (94.4%) at discharge and in 140 patients (94.5%) at 30 d. We did not find predictors of clinical outcomes on multivariate analysis. CONCLUSION: The 30-d rates of neurological morbidity and mortality in this multicenter cohort using the PED Flex for the treatment of intracranial aneurysms were low, 1.9% (4/205) and 0.5% (1/205), respectively. In addition, technical events related to device deployment were also low, most likely due to the latest modifications in the delivery system.


Subject(s)
Intracranial Aneurysm/surgery , Adult , Aged , Angiography , Female , Humans , Intracranial Aneurysm/mortality , Logistic Models , Male , Middle Aged , Multivariate Analysis , Patient Discharge , Retrospective Studies , Treatment Outcome , Young Adult
3.
J Neurointerv Surg ; 11(4): 347-351, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30552167

ABSTRACT

BACKGROUND: Treatment of acute cerebrovascular pathology, such as acute ischemic stroke or intracranial aneurysms, presents a challenge if an extracranial or intracranial stent is required; immediate platelet inhibition is vital. To date, there is no standardized approach for antiplatelet inhibition in an acute setting. OBJECTIVE: To report our preliminary experience and lessons learnt using cangrelor in acute neurointervention. METHODS: A single-arm pilot study was performed to assess the safety and efficacy of cangrelor plus aspirin for platelet inhibition in patients who require acute stenting in the setting of neuroendovascular treatment. RESULTS: Eight patients were enrolled between October 2017 and August 2018. Median age was 71 years (53-86). Seven patients were treated in an acute setting according to the stroke protocol at our institution, while one patient was treated for a symptomatic, unruptured aneurysm with flow diversion and coiling. At admission, the median National Institutes of Health Stroke Scale score for the patients with stroke was 12.5 (range 2-22.3). Cangrelor was infused and all patients achieved adequate platelet inhibition (<200 PRU (P2Y12 reaction units)). Six of seven patients with ischemic stroke had a carotid stent placed and one had an intracranial stent deployed in the middle cerebral artery. None of the patients experienced intraprocedural thromboembolic complications, intraprocedural in-stent thrombosis, hemorrhagic complications, or stroke within 24 hours after the intervention. The majority of patients (6/8) had a good clinical outcome at discharge (modified Rankin Scale score 0-2). CONCLUSIONS: Our findings suggest that cangrelor is a promising alternative in acute stenting for the treatment of cerebrovascular pathology. However, further studies with larger samples are required to accurately elucidate its safety and effectiveness in neuroendovascular procedures.


Subject(s)
Adenosine Monophosphate/analogs & derivatives , Aspirin/administration & dosage , Brain Ischemia/therapy , Platelet Aggregation Inhibitors/administration & dosage , Purinergic P2Y Receptor Antagonists/administration & dosage , Stents , Stroke/therapy , Adenosine Monophosphate/administration & dosage , Adenosine Monophosphate/adverse effects , Adult , Aged , Aged, 80 and over , Aspirin/adverse effects , Brain Ischemia/diagnostic imaging , Drug Therapy, Combination , Endovascular Procedures/methods , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pilot Projects , Platelet Aggregation Inhibitors/adverse effects , Stents/adverse effects , Stroke/diagnostic imaging , Thrombectomy/methods , Treatment Outcome
4.
World Neurosurg ; 115: 341-345, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29751188

ABSTRACT

BACKGROUND: Reversible cerebral vasoconstriction syndrome (RCVS) is a rare entity with an unknown pathophysiology. RCVS has been reported to occur more frequently in women age 20-50 years. Several causative mechanisms have been postulated involving transient deregulation of cerebral arterial tone, small vessel endothelial dysfunction, biochemical factors, hormonal deregulation, oxidative stress, and genetic predisposition. All these mechanisms and triggers are related to sympathetic overactivation, which eventually produces vasoconstriction. RCVS is distinguished by acute severe recurrent thunderclap headaches with or without other neurologic symptoms. However, the diagnosis can be challenging, requiring a high level of suspicion by the clinician, and RCVS is often underdiagnosed. CASE DESCRIPTION: We present an unusual case of an 18-year-old female who developed RCVS after embolization of a dural arteriovenous fistula with onyx embolic material. Cerebral angiography was performed and verapamil was administered intra-arterially, resulting in a slight decrease in vasoconstriction with clinical improvement. The patient was maintained on oral verapamil during hospitalization. At a 7-month follow-up, the patient was neurologically stable, and cerebral angiography demonstrated no signs of vasoconstriction. CONCLUSIONS: Endovascular procedures are a rare trigger for the development of RCVS and may be misdiagnosed. Prompt recognition of symptoms and diagnosis with treatment are necessary to reduce the risk of stroke. The management approach should be based on the premise of discontinuing precipitating drugs and administering calcium channel blocking agents.


Subject(s)
Central Nervous System Vascular Malformations/therapy , Dimethyl Sulfoxide/administration & dosage , Embolization, Therapeutic/methods , Polyvinyls/administration & dosage , Vasoconstriction/physiology , Vasospasm, Intracranial/therapy , Adolescent , Central Nervous System Vascular Malformations/complications , Central Nervous System Vascular Malformations/diagnostic imaging , Female , Humans , Syndrome , Vasoconstriction/drug effects , Vasospasm, Intracranial/diagnostic imaging , Vasospasm, Intracranial/etiology
5.
Cureus ; 9(3): e1092, 2017 Mar 13.
Article in English | MEDLINE | ID: mdl-28413738

ABSTRACT

Cavernous malformations are uncommon vascular lesions with an estimated prevalence of 0.5% in the general population. Intramedullary cavernous malformations (ICM) represent a rare subset of lesions, which account for approximately 5% of all cavernous malformations. The annual risk of hemorrhage in ICMs has been reported to range from 1.4 to 6.8%. Most patients are diagnosed with neurological dysfunction secondary to ICM hemorrhage and little is known about the inciting events that lead to hemorrhage. A few studies have suggested that minor and major trauma or even intense exertion may increase the risk of hemorrhage. We report the case of a 62-year-old male who developed progressive neurological deterioration following a motor vehicle accident. During work-up, an ICM was found at T4 and was surgically removed. At his 10-month follow-up, the patient had partially recovered, regaining motor strength in his right lower extremity, but had a persistent decrease in temperature and pinprick sensation on the left side starting at the T6 dermatome. We hypothesize that ICMs can rupture after high-energy impacts, such as the motor vehicle accident in our patient, and mechanical factors, such as trauma and stretching maneuvers, can play a role in the pathogenesis of ICM hemorrhage.

6.
J Neurointerv Surg ; 9(2): 147-151, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27382125

ABSTRACT

BACKGROUND: The off-label use of flow diverters in the treatment of distal aneurysms continues to be debated. OBJECTIVE: To report our multicenter experience in the treatment of complex anterior cerebral artery aneurysms with the Pipeline embolization device (PED). METHODS: The neurointerventional databases of the four participating institutions were retrospectively reviewed for aneurysms treated with PED between October 2011 and January of 2016. All patients treated for anterior cerebral artery aneurysms were included in the analysis. Clinical presentation, location, type, vessel size, procedural complications, clinical and imaging follow-up were included in the analysis. RESULTS: Twenty patients (13 female) with 20 aneurysms met the inclusion criteria in our study. Fifteen aneurysms were classified as saccular and five as fusiform (mean size 7.3 mm). Thirteen aneurysms were located in the anterior communicating region (ACOM or A1/2 junction), six were A2-pericallosal, and one was located in the A1 segment. Six patients had presented previously with subarachnoid hemorrhage and had their aneurysms initially clipped or coiled. There was one minor event (a small caudate infarct) and one major event (intraparenchymal hemorrhage). Sixteen of the 20 patients had angiographic follow-up (mean 10 months). Eleven aneurysms were completely occluded, one had residual neck, and four had residual aneurysm filling. CONCLUSIONS: The treatment of complex anterior cerebral artery aneurysms with the PED as an alternative for patients who are not good candidates for conventional methods is technically feasible and safe. Mid-term results are promising but larger series with long-term follow-up are required to assess its effectiveness.


Subject(s)
Blood Vessel Prosthesis , Cerebral Hemorrhage/surgery , Infarction, Anterior Cerebral Artery/surgery , Intracranial Aneurysm/surgery , Adult , Aged , Anterior Cerebral Artery/diagnostic imaging , Anterior Cerebral Artery/surgery , Blood Vessel Prosthesis Implantation , Cerebral Angiography , Cerebral Hemorrhage/diagnostic imaging , Cerebral Infarction/etiology , Cerebral Infarction/surgery , Female , Humans , Infarction, Anterior Cerebral Artery/diagnostic imaging , Intracranial Aneurysm/diagnostic imaging , Magnetic Resonance Angiography , Male , Middle Aged , Neurosurgical Procedures/methods , Retrospective Studies
7.
Expert Rev Med Devices ; 13(10): 885-897, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27647130

ABSTRACT

INTRODUCTION: Refinements in endovascular technology have revolutionized the treatment of intracranial aneurysms (IAs) with the development of flow-diversion technology. The first generation of the Pipelin Embolization Device (PED) has demonstrated its safety and efficacy. However, the deployment technique was a difficult task that often led to complex maneuvers. The Pipeline Flex Embolization Device (PED Flex) is the second generation and its introduction has arrived with high expectations due to a completely redesigned delivery system that intends to overcome deployment difficulties seen in the previous generation. Areas covered: Preclinical studies, mechanism of action of flow-diverters, technical aspects and deployment system of the PED Flex, and clinical outcomes with both PED generations. Expert commentary: Flow diversion has allowed us to treat lesions that would be otherwise challenging for surgical clipping or unsuitable for other endosaccular strategies. Although the experience with PED Flex is limited, initial results suggest its safety and short-term efficacy.


Subject(s)
Embolization, Therapeutic/instrumentation , Intracranial Aneurysm/therapy , Animals , Clinical Trials as Topic , Humans , Treatment Outcome
8.
Surg Neurol Int ; 5: 18, 2014.
Article in English | MEDLINE | ID: mdl-24778906

ABSTRACT

BACKGROUND: Chordomas are rare slowly growing tumors that originate from remnants of the notochord. They have a malignant local behavior, causing symptoms due to bone infiltration and compression of neurovascular structures. Only a few cases of brain tumors associated with pathological laughter have been reported in the literature. CASE DESCRIPTION: We report a case of a 42-year-old male patient with this atypical clinical presentation treated at our institution, and discuss the concerning literature. CONCLUSION: Although being a very rare presentation of chordomas, pathological laughter is usually expected to improve after brain stem decompression.

9.
Brasília méd ; 46(3)2009. tab, graf
Article in Portuguese | LILACS | ID: lil-531635

ABSTRACT

Objective. This is a study about the prevention of neural tube defect, the most frequent malformation involving the embryo nervous system. The recommended method of prevention is to take folic acid (0.4 mg/day) three months before conception and during the first three months of pregnancy because the closure of the neural tube occurs between 24 to 28 weeks of pregnancy. Method. Physicians, gynecologists and primary doctors, women in reproductive age from the general population and female college students of health science were asked regarding their knowledge about prevention of neural tube defect. Three hundred and eighteen questionnaires were applied to 56 doctors, and 262 women of reproductive age. Results. Among the doctors interviewed about their knowledge of the prevention of neural tube defect, 28 (50%) responded that they give emphatic guidance on its prevention, 44 (79%) prescribe folic acid to their patients, but only 16 (28.6%) do so in the correct period and only 3 (5.4%) answered that they do not prescribe any form of prevention. In the group of women of reproductive age, only 29 (11.1%) were correctly oriented, while 185 (70.6%) reported they did not take any prevention for neural tube defect . Conclusion. Data from this work showed that prevention of the neural defect is not performed satisfactorily bydoctors or by women of reproductive age.


Objetivo. Foi realizado um estudo sobre o conhecimento da prevenção do defeito do fechamento do tubo neural, que é uma das malformações mais frequentes que envolvem o sistema nervoso do embrião. A prevenção recomendada é feita com ácido fólico (0,4 mg/dia) administrado três meses antes da concepção e no primeiro trimestre da gestação, pois o fechamento do tubo neural ocorre de 24 a 28 semanas de gestação. Método. Foi investigado o conhecimento sobre a prevenção do defeito do fechamento do tubo neural em médicos ginecologistas e do programa de saúde publica, mulheres em idade reprodutiva incluindo acadêmicas da área de saúde e da comunidade em geral. Foram aplicados 318 questionários, sendo 56 para os médicos e 262 para as mulheres em idade reprodutiva. Resultados. Entre os médicos entrevistados sobre o conhecimento da prevenção de defeito do fechamento do tubo neural, 28 (50%) responderam que fazem uma orientação enfática quanto a sua prevenção, 44 (79%) indicam às suas pacientes o ácido fólico, mas apenas 16 (28,6%) o fazem no período correto, e apenas 3 (5,4%) responderam que não indicam nenhuma forma de prevenção. No grupo de mulheres em idade reprodutiva, apenas 29 (11,1%) tinham sido orientadas corretamente, enquanto 185 (70,6%) referiram não fazer qualquer prevenção de defeito do fechamento do tubo neural. Conclusão. Os dados deste trabalho mostraram que a prevenção do defeito em análise não está sendo realizada de forma satisfatória pelos médicos ou pelas mulheres em idade reprodutiva na população estudada.


Subject(s)
Humans , Female , Neural Tube Defects , Neural Tube Defects/prevention & control , Prenatal Diagnosis , Embryonic Structures , Meningomyelocele , Surveys and Questionnaires , Folic Acid , Folic Acid/biosynthesis
SELECTION OF CITATIONS
SEARCH DETAIL
...